Therapy response and prognosis of patients with early breast cancer with low positivity for hormone receptors – An analysis of 2765 patients from neoadjuvant clinical trials

Therapy response and prognosis of patients with early breast cancer with low positivity for hormone receptors – An analysis of 2765 patients from neoadjuvant clinical trials

To evaluate HER2-negative breast cancer (BC) with a low hormone receptor (HR) expression, with regard to pathological complete response (pCR) and survival, in comparison to triple-negative BC (TNBC) and strong HR-positive BC. We compared negative [oestrogen (ER) and progesterone receptor (PR)

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:European journal of cancer (1990) 2021-05, Vol.148, p.159-170
Hauptverfasser: Villegas, Sonia L., Nekljudova, Valentina, Pfarr, Nicole, Engel, Jutta, Untch, Michael, Schrodi, Simone, Holms, Frank, Ulmer, Hans U., Fasching, Peter A., Weber, Karsten E., Albig, Christian, Heinrichs, Clemens, Marmé, Frederik, Hartmann, Arndt, Hanusch, Claus, Schmitt, Wolfgang D., Huober, Jens, Lederer, Bianca, van Mackelenbergh, Marion, Tesch, Hans, Jackisch, Christian, Rezai, Mahdi, Sinn, Peter, Sinn, Bruno V., Hackmann, John, Kiechle, Marion, Schneeweiss, Andreas, Weichert, Wilko, Denkert, Carsten, Loibl, Sibylle
Format: Artikel
Sprache:eng
Schlagworte:
Breast cancer
Breast neoplasms
Cancer biomarkers
Clinical trials
Confidence intervals
ER-negative PR-negative HER2-negative breast cancer
ErbB-2 protein
Estrogens
Gene expression
Gene sequencing
Health hazards
Hormone-dependent neoplasms
Mammary cancer
Medical prognosis
Neoadjuvant therapy
Oestrogen receptors
Progesterone
Progesterone receptors
Rank tests
Receptors
Ribonucleic acid
RNA
Survival
Triple-negative breast cancer
Tumors
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:To evaluate HER2-negative breast cancer (BC) with a low hormone receptor (HR) expression, with regard to pathological complete response (pCR) and survival, in comparison to triple-negative BC (TNBC) and strong HR-positive BC. We compared negative [oestrogen (ER) and progesterone receptor (PR)
ISSN:0959-8049
1879-0852
DOI:10.1016/j.ejca.2021.02.020